Acute Anterior Choroidal Infarction (ACI), Paramedian Pontine Infarction (IPP)
Conditions
Keywords
anterior choroidal infarction, paramedian pontine infarction, intravenous thrombolysis, tirofiban
Brief summary
TITACIPPI (Tirofiban with Intravenous Thrombolysis in Acute Anterior Choroidal Infarction \[ACI\] and Paramedian Pontine Infarction \[IPP\]) study aimed to evaluate the efficacy and safety of simultaneous infusion of tirofiban with intravenous thrombolysis (IVT + tirofiban group) compared to IVT alone (IVT alone group) in patients with ACI or PPI. TITACIPPI study is a retrospective, single-center observational study conducted from March 01, 2014, to December 31, 2022.
Detailed description
ACI and PPI are frequently associated with clinical fluctuations, characterized by recurrent transient more or less regressive stereotyped episodes of focal motor deficits affecting the face, arm, and leg, and finally with a risk of lasting neurological worsening that can lead to definite residual neurological disability. These ischemic strokes (ACI and PPI) are not very sensitive to IVT, thus 26% to 48% will experience neurological aggravation despite the administration of this treatment. Studies in Asia have shown a possible clinical benefit of simultaneous infusion of tirofiban with IVT in patients with ischemic stroke of atheromatous or microatheromatous origin without additional bleeding risk. To date, no studies have tested the efficacy of simultaneous infusion of tirofiban and IVT in the well-defined subgroup of ACI and PPI and a non-Asian population.
Interventions
PROCEDUREIVT with tenecteplase or alteplase
Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
PROCEDUREIntervention Name : Tirofiban and IVT with tenecteplase or alteplase
IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
Sponsors
Centre Hospitalier Sud Francilien
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged ≥ 18 years with ACI or PPI between March 01, 2014 and December 31, 2022. * Patients hospitalized in the stroke unit of Centre Hospitalier Sud Francilien in the acute phase of their ischemic stroke (FLAIR negative on the pre-treatment brain MRI allowing IVT). * Patients with NIHSS ≥ 2 on admission * Patients treated with IVT * For the experimental group: patients treated with tirofiban at 0.4 μg/kg/min with the start of infusion within 1 hour of IVT initiation. * Patients with post-treatment brain MRI within 24-36h.
Exclusion criteria
* Patients with contraindications to IVT (cardiac, thoracic or digestive surgery less than 14 days old, thrombocytopenia \< 100,000/mm3, etc.). * Absence of MRI as initial imaging. * Less than 24 hours of continuous infusion of tirofiban. * Patients at high risk of cerebral hemorrhage: severe microangiopathy (Fazekas Score 3), microbleeds \> 5, or leptomeningeal hemosiderosis suggestive of amyloid angiopathy. * Patients with pre-stroke mRS ≥ 3. * Patients informed of the research and objecting to the collection of their data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Volume of the ischemic lesion | at 24 hours | Evolution of the volume of the ischemic lesion in diffusion-weighted imaging between initial MRI and post-therapy MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| NIHSS | at day 7 | NIHSS (from 0=favorable to 42=unfavorable) |
| Modified Rankin Scale (mRS) | at 3 months | Proportion of the patients with mRS 0-2 |
| Secondary neurological deterioration | at 72 hours | Rate of secondary neurological deterioration (fluctuations or neurological progression defined as an increase of at least 1 point in NIHSS). |
| Cerebral hemorrhages | at 24 hours | Rates of cerebral hemorrhages defined according to the Heidelberg Bleeding Classification |
| Systemic bleedings | at 24 hours | Rate of significant systemic bleeding (i.e., requiring specific treatment). |
Countries
France
Outcome results
None listed